Morria Biopharmaceuticals Plc. Announces Initiation of Its Phase II Study in Contact Dermatitis Patients Using MRX6, a Nov

LONDON & NEW YORK--(BUSINESS WIRE)-- Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today the initiation of its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6. The double-blind, placebo-controlled study of up to 80 contact dermatitis patients will take place at the Hadassah Hospital in Israel. A previous pilot clinical study demonstrated that a topical preparation of MRX6, applied twice daily for 28 days, scored 69% improvement based on conventional Physician’s Assessment versus a standard 30% placebo effect generated by the vehicle. The upcoming study will examine a shortened b.i.d regime of 21 days as well as look at pharmacokinetics and dose-response parameters.

“This is our latest positive news in the clinical development of our unique and novel products” said Yuval Cohen, President of Morria. “We look forward to reporting the results of the phase II study and partnering with a company for the marketing of MRX6”.

ABOUT CONTACT DERMATITIS

Contact dermatitis is an allergic condition in which patients develop skin reactions when coming into contact with certain materials/substances such as metals, latex and fabrics. The market for this condition is estimated at $600m.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focusing on the development of anti-inflammatory agents termed Multi-Functional Anti-Inflammatory Drugs (MFAID). Morria is determined to use its unique technological and cost advantage to become a major player in the $50bn anti-inflammatory drug market within the next decade through the introduction of novel drugs for the treatment of a variety of chronic inflammatory conditions including skin, airway, eye and gastro-intestinal inflammatory diseases.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information.



CONTACT:

Morria Biopharmaceuticals Plc
Yuval Cohen, President
T: +44 (0)207 152 6341 or
E: [email protected]
W: http://www.morria.com

KEYWORDS:   United Kingdom  United States  Europe  North America  Middle East  Israel

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.